Weill Medical College of Cornell University

• Home
• Cancer and Blood Disorders
  • Solid Tumor
    • Bladder Cancer
    • Breast Cancer
    • Colon Cancer
    • Esophageal Cancer
    • Gastric/Stomach Cancer
    • Head and Neck Cancer
    • Kidney/Renal Cancer
    • Liver Cancer
    • Lung Cancer
    • Melanoma
    • Ovarian/Peritoneal/Fallopian Tube Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Sarcoma
    • Soft Tissue Cancer

  • Multiple Myeloma
  • Leukemia and Myeloproliferative Disorders
    • Acute Lymphocytic Leukemia
    • Acute Myeloid Leukemia
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Chronic Myeloid Leukemia
    • Myelodysplastic Syndrome
    • Myelofibrosis
    • Polycythemia Vera

  • Lymphoma
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Hodgkin’s Lymphoma
    • Non-Hodgkin’s Lymphoma
    • Waldenstrom’s Macroglobulinemia

  • Bone Marrow Transplant (BMT)
  • Benign Hematology
    • Anticoagulation
    • Bleeding and Platelet Disorders
• Cardiovascular/Heart
  • Aortic Aneurysms
  • Arrhythmias
  • Atrial Fibrillations
  • Coronary Artery Disease (CAD)
  • Inherited Heart Disease
  • Myocardial Infarction
  • Other Cardiovascular Diseases and Conditions
• Diabetes
• Gastrointestinal Diseases
  • Hepatitis
    • Hepatitis B
    • Hepatitis C
    • Hepatitis/HIV Co-Infection
  • Cancers of the Colon, Pancreas, Esophagus, Stomach
  • Celiac Disease
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Ulcerative Colitis
  • Other Gastrointestinal Diseases
• Geriatrics
  • Pain and Palliative Care
• Hepatitis
  • Hepatitis B
  • Hepatitis C
  • Hepatitis/HIV Co-infection
• Hypertension/High Blood Pressure
• HIV/AIDS and Infectious Diseases
• Kidney/Renal Disease
  • Kidney Transplants
• Lifestyle/Behavior Change
  • Medication Adherence
  • Hypertension Control
  • Colon Cancer Screening/Risk Reduction
• Pulmonary (Lung/Respiratory Tract) Disease
  • Asthma
  • Pneumonia
  • Pulmonary Fibrosis
  • Smokers
  • Other Respiratory/Lung Conditions
• Rheumatology Autoimmune Disease and Orthopedic Surgery
 
• Sleep Disorders
• Weight Loss/Obesity
• Healthy Volunteers

A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms

Study Status

Open to Enrollment

Study Description

The purpose of this clinical trial is to determine if an investigational drug called LY2874544 can help patients with myeloproliferative neoplasms (MPNs). The study will also help determine the safety of LY2874544 and any side effects that might be associated with it.

LY2874544 inhibits a mutant protein that is found in a majority of non-chronic myeloid leukemia MPN patients. Inhibiting this mutant protein may bring about a better response in patients with MPN.

All patients in the study will receive LY2874544. The drug is taken orally once a day. The dose a patient receives will depend on the cohort that is open for enrollment when the patient has been determined to be eligible.

Patients will be in the study for approximately 30 weeks. Patients may stay on the study as long as they are benefiting from the study drug.

Disease Status and/or Stage

Polycythemia Vera (PV), Essential Thrombocythemia (ET), or Myelofibrosis (MF)

Sponsor

Ely Lilly

Key Eligibility

• Diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF)
• PV: have failed or is unable to tolerate standard therapies
• ET: have failed or is unable to tolerate standard therapies
• MF: must meet one of the following:
• Have intermediate 1, intermediate 2 or high-risk MF
• Have symptomatic MF
• Have post-polycythemic MF
• Have post-ET MF
• Men and women age 18 or older
• Detailed eligibility reviewed when you contact the study team

Principal Investigator

Ellen Ritchie, MD

Contact

• Tania Curcio, RN
• (212) 746-2571
• [email protected]